Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1987 Nov;80(5):1492–1497. doi: 10.1172/JCI113231

Activation of terminal components of complement in patients with Guillain-Barré syndrome and other demyelinating neuropathies.

C L Koski 1, M E Sanders 1, P T Swoveland 1, T J Lawley 1, M L Shin 1, M M Frank 1, K A Joiner 1
PMCID: PMC442409  PMID: 3680509

Abstract

In the present study, the role of antiperipheral nerve myelin antibody (anti-PNM Ab) in demyelination by generating the terminal attack complex (C5b-9) of complement was explored in patients with Guillain-Barré syndrome (GBS) and other demyelinating neuropathies. The presence in serum of SC5b-9, an inactive C5b-9 containing S protein, was assessed quantitatively by enzyme-linked immunosorbent assay using an antibody (Ab) to neoantigens expressed on C9 when complexed with C5b-8 or after tubular polymerization. SC5b-9 was detected in all 19 GBS, four patients with paraprotein-associated neuropathy and five of six patients with chronic recurrent polyneuritis. No SC5b-9 was detected in 10 normal controls. Kinetic studies from six GBS patients showed the highest values of SC5b-9 on the 3rd to 5th d of admission; in contrast, the anti-PNM Ab were highest on the day of admission. Anti-PNM Ab fell rapidly to very low levels by the 15th to 20th d. SC5b-9 declined with similar kinetics to undetectable levels by the 30th d. Levels of Ab and SC5b-9 did not quantitatively correlate with soluble immune complexes in these patients' serum. Membrane-bound C5b-9 was also detected by immunohistochemistry in the peripheral nerves from a GBS patient. These results, which show a relationship between levels of complement-fixing anti-PNM Ab and the tissue-damaging C5b-9 complex, suggest that peripheral nerve myelin may serve as the target for Ab-mediated complement attack.

Full text

PDF
1492

Images in this article

1495Image
on p.1495

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bhakdi S., Tranum-Jensen J. On the cause and nature of C9-related heterogeneity of terminal complement complexes generated on target erythrocytes through the action of whole serum. J Immunol. 1984 Sep;133(3):1453–1463. [PubMed] [Google Scholar]
  2. Biesecker G., Katz S., Koffler D. Renal localization of the membrane attack complex in systemic lupus erythematosus nephritis. J Exp Med. 1981 Dec 1;154(6):1779–1794. doi: 10.1084/jem.154.6.1779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Biesecker G., Lavin L., Ziskind M., Koffler D. Cutaneous localization of the membrane attack complex in discoid and systemic lupus erythematosus. N Engl J Med. 1982 Feb 4;306(5):264–270. doi: 10.1056/NEJM198202043060503. [DOI] [PubMed] [Google Scholar]
  4. Borsos T., Rapp H. J. Hemolysin titration based on fixation of the activated first component of complement: evidence that one molecule of hemolysin suffices to sensitize an erythrocyte. J Immunol. 1965 Sep;95(3):559–566. [PubMed] [Google Scholar]
  5. Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol. 1978 Jun;3(6):565–566. doi: 10.1002/ana.410030628. [DOI] [PubMed] [Google Scholar]
  6. Curd J. G., Sundsmo J. S., Kolb W. P., Bluestein H. G., Müller-Eberhard H. J. Neoantigen of the membrane attack complex of human complement: Occurrence on peripheral blood leukocytes from patients with systemic lupus erythematosus. Arthritis Rheum. 1978 Mar;21(2):177–182. doi: 10.1002/art.1780210201. [DOI] [PubMed] [Google Scholar]
  7. Engel A. G., Biesecker G. Complement activation in muscle fiber necrosis: demonstration of the membrane attack complex of complement in necrotic fibers. Ann Neurol. 1982 Sep;12(3):289–296. doi: 10.1002/ana.410120314. [DOI] [PubMed] [Google Scholar]
  8. Falk R. J., Dalmasso A. P., Kim Y., Tsai C. H., Scheinman J. I., Gewurz H., Michael A. F. Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. J Clin Invest. 1983 Aug;72(2):560–573. doi: 10.1172/JCI111004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Feasby T. E., Hahn A. F., Gilbert J. J. Passive transfer studies in Guillain-Barré polyneuropathy. Neurology. 1982 Oct;32(10):1159–1167. doi: 10.1212/wnl.32.10.1151-a. [DOI] [PubMed] [Google Scholar]
  10. Hsu S. M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981 Apr;29(4):577–580. doi: 10.1177/29.4.6166661. [DOI] [PubMed] [Google Scholar]
  11. Kolb W. P., Muller-Eberhard H. J. The membrane attack mechanism of complement. Isolation and subunit composition of the C5b-9 complex. J Exp Med. 1975 Apr 1;141(4):724–735. [PMC free article] [PubMed] [Google Scholar]
  12. Koski C. L., Gratz E., Sutherland J., Mayer R. F. Clinical correlation with anti-peripheral-nerve myelin antibodies in Guillain-Barré syndrome. Ann Neurol. 1986 Jun;19(6):573–577. doi: 10.1002/ana.410190609. [DOI] [PubMed] [Google Scholar]
  13. Koski C. L. Guillain-Barré syndrome. Neurol Clin. 1984 May;2(2):355–366. [PubMed] [Google Scholar]
  14. Koski C. L., Humphrey R., Shin M. L. Anti-peripheral myelin antibody in patients with demyelinating neuropathy: quantitative and kinetic determination of serum antibody by complement component 1 fixation. Proc Natl Acad Sci U S A. 1985 Feb;82(3):905–909. doi: 10.1073/pnas.82.3.905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Koski C. L., Vanguri P., Shin M. L. Activation of the alternative pathway of complement by human peripheral nerve myelin. J Immunol. 1985 Mar;134(3):1810–1814. [PubMed] [Google Scholar]
  16. Latov N., Gross R. B., Kastelman J., Flanagan T., Lamme S., Alkaitis D. A., Olarte M. R., Sherman W. H., Chess L., Penn A. S. Complement-fixing antiperipheral nerve myelin antibodies in patients with inflammatory polyneuritis and with polyneuropathy and paraproteinemia. Neurology. 1981 Dec;31(12):1530–1534. doi: 10.1212/wnl.31.12.1530. [DOI] [PubMed] [Google Scholar]
  17. Latov N., Sherman W. H., Nemni R., Galassi G., Shyong J. S., Penn A. S., Chess L., Olarte M. R., Rowland L. P., Osserman E. F. Plasma-cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral-nerve myelin. N Engl J Med. 1980 Sep 11;303(11):618–621. doi: 10.1056/NEJM198009113031105. [DOI] [PubMed] [Google Scholar]
  18. Lawley T. J., Moutsopoulos H. M., Katz S. I., Theofilopoulos A. N., Chused T. M., Frank M. M. Demonstration of circulating immune complexes in Sjögren's syndrome. J Immunol. 1979 Sep;123(3):1382–1387. [PubMed] [Google Scholar]
  19. MELNICK S. C. Thirty-eight cases of the Guillain-Barre syndrome: an immunological study. Br Med J. 1963 Feb 9;1(5327):368–373. doi: 10.1136/bmj.1.5327.368. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. McGarry R. C., Helfand S. L., Quarles R. H., Roder J. C. Recognition of myelin-associated glycoprotein by the monoclonal antibody HNK-1. Nature. 1983 Nov 24;306(5941):376–378. doi: 10.1038/306376a0. [DOI] [PubMed] [Google Scholar]
  21. Mollnes T. E., Lea T., Frøland S. S., Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol. 1985 Aug;22(2):197–202. doi: 10.1111/j.1365-3083.1985.tb01871.x. [DOI] [PubMed] [Google Scholar]
  22. Müller-Eberhard H. J. The membrane attack complex. Springer Semin Immunopathol. 1984;7(2-3):93–141. doi: 10.1007/BF01893017. [DOI] [PubMed] [Google Scholar]
  23. Nobile-Orazio E., Hays A. P., Latov N., Perman G., Golier J., Shy M. E., Freddo L. Specificity of mouse and human monoclonal antibodies to myelin-associated glycoprotein. Neurology. 1984 Oct;34(10):1336–1342. doi: 10.1212/wnl.34.10.1336. [DOI] [PubMed] [Google Scholar]
  24. Podack E. R., Tschoop J., Müller-Eberhard H. J. Molecular organization of C9 within the membrane attack complex of complement. Induction of circular C9 polymerization by the C5b-8 assembly. J Exp Med. 1982 Jul 1;156(1):268–282. doi: 10.1084/jem.156.1.268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sanders M. E., Kopicky J. A., Wigley F. M., Shin M. L., Frank M. M., Joiner K. A. Membrane attack complex of complement in rheumatoid synovial tissue demonstrated by immunofluorescent microscopy. J Rheumatol. 1986 Dec;13(6):1028–1034. [PubMed] [Google Scholar]
  26. Sanders M. E., Koski C. L., Robbins D., Shin M. L., Frank M. M., Joiner K. A. Activated terminal complement in cerebrospinal fluid in Guillain-Barré syndrome and multiple sclerosis. J Immunol. 1986 Jun 15;136(12):4456–4459. [PubMed] [Google Scholar]
  27. Sanders M. E., Schmetz M. A., Hammer C. H., Frank M. M., Joiner K. A. Quantitation of activation of the human terminal complement pathway by ELISA. J Immunol Methods. 1985 Dec 27;85(2):245–256. doi: 10.1016/0022-1759(85)90135-8. [DOI] [PubMed] [Google Scholar]
  28. Searles R. P., Davis L. E., Hermanson S., Froelich C. J. Lymphocytotoxic antibodies in Guillain-Barré syndrome. Lancet. 1981 Jan 31;1(8214):273–273. doi: 10.1016/s0140-6736(81)92107-3. [DOI] [PubMed] [Google Scholar]
  29. Shin M. L., Paznekas W. A., Abramovitz A. S., Mayer M. M. On the mechanism of membrane damage by C: exposure of hydrophobic sites on activated C proteins. J Immunol. 1977 Oct;119(4):1358–1364. [PubMed] [Google Scholar]
  30. Tschopp J., Müller-Eberhard H. J., Podack E. R. Formation of transmembrane tubules by spontaneous polymerization of the hydrophilic complement protein C9. Nature. 1982 Aug 5;298(5874):534–538. doi: 10.1038/298534a0. [DOI] [PubMed] [Google Scholar]
  31. Vanguri P., Koski C. L., Silverman B., Shin M. L. Complement activation by isolated myelin: activation of the classical pathway in the absence of myelin-specific antibodies. Proc Natl Acad Sci U S A. 1982 May;79(10):3290–3294. doi: 10.1073/pnas.79.10.3290. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES